Clinical Trial Update: Study Comparing Graft Function in Renal Allograft Recepients Receiving Reduced or Standard Dose CsA With Sirolimus [Phase 4]

View source ↗

Summary

Phase 4 trial comparing reduced versus standard dose cyclosporine with sirolimus in kidney transplant patients assessing graft function; completed study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplantation

Drugs mentioned

• CSA (cyclosporine A)
• Sirolimus (Sirolimus)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Kidney Transplantation | Phase 4 | Status: COMPLETED